Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience,Trupti Rekha Swain1, Siddhartha Goutam1, Rabindra Kumar Jena2, Niranjan Rout3: Indian Journal of Pharmacology

Home

SHORT COMMUNICATION	[View FULLTEXT] [Download PDF]

Year : 2022 \| Volume : 54 \| Issue : 5 \| Page : 349--352

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience

Trupti Rekha Swain¹, Siddhartha Goutam¹, Rabindra Kumar Jena², Niranjan Rout³
¹ Department of Pharmacology, SCB Medical College, Cuttack, Odisha, India
² Department of Clinical Haematology, SCB Medical College, Cuttack, Odisha, India
³ Acharya Harihar Regional Cancer Centre, Cuttack, Odisha, India

Correspondence Address:
Niranjan Rout
Acharya Harihar Regional Cancer Centre, Cuttack, Odisha
India

BACKGROUND: Imatinib mesylate is the cornerstone therapy in the management of chronic myeloid leukemia (CML). Monitoring of adverse drug reactions (ADRs) of imatinib in our patients is very important to ensure their safety. Aims and Objectives: The current study aims to monitor ADRs encountered in CML patients in the chronic phase with imatinib (400 mg/day). MATERIALS AND METHODS: This prospective, observational study was conducted from November 2011 to May 2015 on 310 patients presented to the Departments of Clinical Hematology and Pharmacology of SCB MCH, Cuttack, diagnosed with CML at chronic phase. Collected ADRs were entered in the ADR reporting form (PvPI) and were analyzed for causality and severity. RESULTS: Anemia was the most common hematological ADR, whereas hyperpigmentation and nausea were the most common nonhematological ADRs reported. Maximum ADRs were mild to moderate and required no change in the treatment course. CONCLUSION: The study revealed that imatinib mesylate, a well tolerated drug, has very few cases of severe ADRs in Indian patients at the chronic stable phase of CML.

How to cite this article:
Swain TR, Goutam S, Jena RK, Rout N. Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience.Indian J Pharmacol 2022;54:349-352

How to cite this URL:
Swain TR, Goutam S, Jena RK, Rout N. Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience. Indian J Pharmacol [serial online] 2022 [cited 2023 Mar 25 ];54:349-352
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2022;volume=54;issue=5;spage=349;epage=352;aulast=Swain;type=0